Investigating how SERBP1 affects gene regulation in glioblastoma
SERBP1 as a dual modulator of epigenetic regulation in glioblastoma
This study is looking at a protein called SERBP1 to see how it affects brain cancer stem cells and makes glioblastoma more aggressive, with the hope that understanding this could lead to better treatments for patients like you.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11139745 on NIH RePORTER |
What this research studies
This research focuses on the role of the RNA binding protein SERBP1 in glioblastoma (GBM), a type of brain cancer. It aims to understand how SERBP1 influences the differentiation of cancer stem cells and contributes to the aggressive nature of GBM. By using advanced techniques like RNA sequencing and ATAC sequencing, the researchers will explore the epigenetic mechanisms through which SERBP1 operates, potentially revealing new pathways that could be targeted for treatment. Patients may benefit from insights gained about the molecular underpinnings of their condition, which could lead to more effective therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma, particularly those with high levels of SERBP1 expression.
Not a fit: Patients with other types of brain tumors or those without glioblastoma may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that improve outcomes for patients with glioblastoma.
How similar studies have performed: Previous research has shown promising results in targeting epigenetic factors in cancer, suggesting that this approach could yield significant insights.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Penalva, Luiz Otavio — University of Texas Hlth Science Center
- Study coordinator: Penalva, Luiz Otavio
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.